Fund, Lp Funicular Net Worth

The estimated Net Worth of Fund, Lp Funicular is at least $4.67 Million dollars as of 1 April 2022. Fund Funicular owns over 122,342 units of ARCA biopharma Inc stock worth over $4,667,983 and over the last 3 years Fund sold ABIO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fund Funicular ABIO stock SEC Form 4 insiders trading

Fund has made over 1 trades of the ARCA biopharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Fund bought 122,342 units of ABIO stock worth $276,493 on 1 April 2022.

The largest trade Fund's ever made was buying 122,342 units of ARCA biopharma Inc stock on 1 April 2022 worth over $276,493. On average, Fund trades about 122,342 units every 0 days since 2022. As of 1 April 2022 Fund still owns at least 1,944,993 units of ARCA biopharma Inc stock.

You can see the complete history of Fund Funicular stock trades at the bottom of the page.

What's Fund Funicular's mailing address?

Fund's mailing address filed with the SEC is 2261 MARKET STREET, #4307, SAN FRANCISCO, CA, 94114.

Insiders trading at ARCA biopharma Inc

Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.

What does ARCA biopharma Inc do?

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.

Complete history of Fund Funicular stock trades at ARCA biopharma Inc

ARCA biopharma Inc executives and stock owners

ARCA biopharma Inc executives and other stock owners filed with the SEC include:

• Michael Bristow,
  President, Chief Executive Officer, Director
• Dr. Michael R. Bristow M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Thomas A. Keuer,
  Chief Operating Officer
• Christopher Ozeroff,
  Senior Vice President, General Counsel, Secretary
• Christopher D. Ozeroff,
  Sr. VP, Gen. Counsel & Sec.
• Raymond Woosley,
  Director
• Daniel Mitchell,
  Director
• Anders Hove,
  Director
• Linda Grais,
  Lead Independent Director
• Brian Selby,
  Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
• Thomas Keuer,
  Chief Operating Officer
• Robert Conway,
  Chairman of the Board
• Dr. Debra Marshall FACC, M.D.,
  Chief Medical Officer
• C. Jeffrey Dekker,
  Chief Financial Officer
• Henderson Group Plc Janus H...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Healthcare Capital Partners...,
  
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• Equity Opportunities Fund I...,
  
• Jean Francois Formela,
  Director
• Kathryn E Falberg,
  CFO and COO
• J William Freytag,
  Director
• Mary K Pendergast,
  Director
• Patrick M Wheeler,
  acting Chief Financial Officer
• Riley Mccormack,
  10% owner
• David George Lowe,
  Director
• Burton E Sobel,
  Director
• Venture Fund Vii L P Atlas,
  10% owner
• Richard B Brewer,
  Director
• John L Zabriskie,
  Director
• Venture Partners Qualified ...,
  10% owner
• Ted W Love,
  Director
• Funds, Lp Ma Weaver Jacob F...,
  
• Jacob Ma Weaver,
  
• Fund, Lp Funicular,
  
• C. Jeffrey Dekker,
  Chief Financial Officer
• Fund, Lp Ma Weaver Jacob Fu...,
  
• Funds, Lp Funicular,
  10% owner
• James P Flynn,
  Director